Literature DB >> 7192154

Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces.

T J Hamblin, A K Abdul-Ahad, J Gordon, F K Stevenson, G T Stevenson.   

Abstract

Tumour-specific antiserum was raised in sheep against idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes from a patient with chronic lymphocytic leukaemia (prolymphocytic variant). The complement-activating IgG1 subclass of the anti-idiotype was prepared from the serum in monodisperse form for infusion. Two treatments of 480 and 1200 mg caused the white-cell count to fall by one-third and one-half respectively. However, there was a rapid resurgence, so that by 8 days after each treatment the counts were restored to approximately 85% of their former levels. No change was noted in the size of spleen or lymph nodes. Each treatment probably destroyed 4-8 X 10(11) cells, some 10% of the total tumour load. The antibody was rapidly consumed, and there was evidence of heavy utilization of complement.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7192154      PMCID: PMC2010447          DOI: 10.1038/bjc.1980.271

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  28 in total

1.  Prolymphocytic leukaemia.

Authors:  D A Galton; J M Goldman; E Wiltshaw; D Catovsky; K Henry; G J Goldenberg
Journal:  Br J Haematol       Date:  1974-05       Impact factor: 6.998

2.  Kinetics of lymphocytes in chronic lymphocytic leukemia. I. Equilibrium between blood and a "readily accessible pool".

Authors:  J Manaster; J Frühling; P Stryckmans
Journal:  Blood       Date:  1973-03       Impact factor: 22.113

3.  A factor preventing the development of lung metastases in rats with sarcomas.

Authors:  J W Proctor; C M Rudenstam; P Alexander
Journal:  Nature       Date:  1973-03-02       Impact factor: 49.962

4.  7S anti-tumour antibodies and activated Fc in macrophage tumour cell interaction.

Authors:  O Fakhri; H McLaughlin; J R Hobbs
Journal:  Eur J Cancer       Date:  1973-01       Impact factor: 9.162

5.  Leukocyte labeling with 51 chromium. IV. The kinetics of chronic lymphocytic leukemic lymphocytes.

Authors:  J L Scott; R McMillan; J V Marino; J G Davidson
Journal:  Blood       Date:  1973-01       Impact factor: 22.113

6.  Kinetics of lymphocytes in chronic lymphocytic leukemia: studies using continuous 3H-thymidine infusion in two patients.

Authors:  H Themi; F Trepel; P Schick; W Kaboth; H Begemann
Journal:  Blood       Date:  1973-10       Impact factor: 22.113

7.  C3 shunt activation in human serum chelated with EGTA.

Authors:  D P Fine; S R Marney; D G Colley; J S Sergent; R M Des Prez
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

8.  Chemical coupling of proteins to agarose.

Authors:  J Porath; R Axen; S Ernback
Journal:  Nature       Date:  1967-09-30       Impact factor: 49.962

9.  Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia.

Authors:  H M Grey; E Rabellino; B Pirofsky
Journal:  J Clin Invest       Date:  1971-11       Impact factor: 14.808

10.  Serum-mediated leukemia cell destruction in AKR mice.

Authors:  R L Kassel; L J Old; E A Carswell; N C Fiore; W D Hardy
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

View more
  31 in total

1.  Immunoglobulin idiotype expression in reactive lymphoid tissues and B-cell lymphomas.

Authors:  M Shiota; K Kitamura; M Noda; Y Kawanishi; S Hart; R A Miller; S Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

2.  Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Authors:  M A Ghetie; E M Podar; A Ilgen; B E Gordon; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 3.  Modern management of non-Hodgkin's lymphoma.

Authors:  G M Mead; J M Whitehouse
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-06

4.  Anti-idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy.

Authors:  C H Janson; M J Tehrani; H Mellstedt; H Wigzell
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 5.  Possible role of anti-idiotypic antibodies in the induction of tumor immunity.

Authors:  R C Kennedy; E M Zhou; R E Lanford; T C Chanh; C A Bona
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

Review 6.  Human tumor-associated antigens identified by monoclonal antibodies.

Authors:  K E Hellström; I Hellström; J P Brown
Journal:  Springer Semin Immunopathol       Date:  1982

Review 7.  Treatment of lymphoid tumors with anti-idiotype antibodies.

Authors:  G T Stevenson; F K Stevenson
Journal:  Springer Semin Immunopathol       Date:  1983

8.  Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses.

Authors:  Francesco Forconi; Catherine A King; Surinder S Sahota; Christopher K Kennaway; Nigel H Russell; Freda K Stevenson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 9.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Experimental treatment of chronic lymphocytic leukemia with extracorporeal photochemotherapy. Initial observations.

Authors:  R M Knobler; R Pirker; E M Kokoschka; H Ludwig; W Linkesch; M Micksche
Journal:  Blut       Date:  1990-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.